Bildkälla: Stockfoto

Cantargia: Promising Early Results from CIRIFOUR - Redeye

Redeye provides a comment on the interim clinical update from CIRIFOUR, in which nadunolimab is combined with a checkpoint inhibitor.

Redeye provides a comment on the interim clinical update from CIRIFOUR, in which nadunolimab is combined with a checkpoint inhibitor.
Börsvärldens nyhetsbrev
ANNONSER